These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 732010)

  • 1. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pyridoxine on the depletion of tissue pyridoxal phosphate by carbidopa.
    Airoldi L; Watkins CJ; Wiggins JF; Wurtman RJ
    Metabolism; 1978 Jul; 27(7):771-9. PubMed ID: 661563
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH; Stokes AL
    Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract]   [Full Text] [Related]  

  • 7. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOPA decarboxylase activity in the nervous system and the ctenidium of the freshwater clam, Musculium (Sphaerium) transversum.
    Paparo AA; Murphy JA; Dean RC
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1984; 77(1):55-7. PubMed ID: 6141881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
    Polleri A; Masturzo P; Murialdo G; Carolei A
    Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey.
    Bronaugh RL; Wenger GR; Garver DL; Rutledge CO
    Biochem Pharmacol; 1976 Jul; 25(14):1679-81. PubMed ID: 821489
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase.
    Waterhouse MJ; Chia YC; Lees GJ
    Mol Pharmacol; 1979 Jan; 15(1):108-14. PubMed ID: 423884
    [No Abstract]   [Full Text] [Related]  

  • 12. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of L-dopa and an inhibitor of peripheral decarboxylation on glucose metabolism in brain.
    Tyce GM
    J Neurochem; 1976 Dec; 27(6):1397-403. PubMed ID: 1003214
    [No Abstract]   [Full Text] [Related]  

  • 14. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-DOPA: centrally mediated emission of seminal fluid in male rats.
    Friedman E; Gershon S
    Life Sci I; 1972 May; 11(9):435-40. PubMed ID: 4656863
    [No Abstract]   [Full Text] [Related]  

  • 16. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
    Magnussen I; Van Woert MH
    Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
    Juorio AV
    Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
    Casanueva F; Villanueva L; Peñalva A; Barrionuevo JA; Vila T; Cabezas-Cerrato J
    Rev Clin Esp; 1979 May; 153(3):221-4. PubMed ID: 482695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.